Eleni Efstathiou is a Professor of Cancer Medicine and Chief of the Genitourinary Medical Oncology section at the Houston Methodist Cancer Center. She is internationally known for her breakthrough translational research in prostate cancer, with practices on both sides of the Atlantic. She established and directs a state-of-the-art GU Medical Oncology clinic affiliated to the MD Anderson Cancer Center within the Athens Medical Centre.
Prof. Efstathiou’s main research has been novel androgen signalling inhibition treatment as a tool to guide marker-driven treatment strategies in prostate cancer, and genomic and non-genomic pathways of resistance. Over the past 10 years, Prof. Efstathiou has developed two major clinical trial platforms in the bone metastatic and locally advanced disease setting and has been performing “companion” studies exploring the impact of novel therapeutic agents on the tumour microenvironment and association with pre-treatment molecular characteristics. She is currently Principal Investigator (PI) of two large phase 3 trials testing the advantage of combinatorial androgen signalling inhibition in advanced prostatic carcinoma. She has published >150 manuscripts in peer-reviewed journals.
Prof. Efstathiou is the recipient of the Young Investigator Award and a Career Development Award awarded by the Prostate Cancer Foundation (PCF) and a PI/co-PI on PCF Challenge Awards. She is a European Society of Medical Oncology (ESMO) Academy faculty member and a founding and scientific committee member of the St Gallen Advanced Prostate Cancer Consensus Conference. Of note, she is the only physician scientist to present her work orally at nine consecutive American Society of Clinical Oncology annual meetings. She also serves as the Chair of the GU Prostate Track Scientific Committee for ESMO 2021 and remains an ESMO committee member since the past 10 years.
EM-123253 - Date of preparation: February 2023